AI in Clinical Research: What's Real in 2026

If you work in clinical research, you have seen both halves of the AI conversation. One half is vendor decks: 65% enrollment improvement, 40% cost reduction, agents that handle a CRA's admin. The other half is Reddit threads where people who do your job ask whether it will still exist in five years. This article separates the two.

The problem AI is being sold against is real, though even the framing statistics deserve scrutiny. Around 80% of trials miss their enrollment timelines, per one industry compilation from DataAlly, which is itself an AI vendor's blog rather than a primary study. The best-sourced number in this set: Tufts CSDD estimated in 2024 that a single day of Phase III delay costs about $55,700 in direct trial conduct, plus about $800,000 in lost prescription drug sales. One vendor blog also claims screen-failure rates above 40% can add roughly $1.2 million per study; no primary source backs that figure, so treat it as a pitch, not a fact.

One disclosure before anything else: almost every number circulating about AI in trials originates with the company selling the tool. Medable's "ultimate guide" is typical of the genre. This article sticks to peer-reviewed work, regulators, and practitioners posting under their own job titles.

How are people in clinical research actually using AI right now?

This is the most-asked professional question on r/clinicalresearch, and the answers are smaller and more useful than the marketing.

CRAs and monitors

When CRAs compare notes, the uses they report are narrow: checking concomitant meds against a protocol's prohibited list, summarizing a 200-page protocol before a visit, drafting visit confirmation letters, and writing the Excel formulas and VBA they would otherwise search for. Nobody in that thread describes an agent running a monitoring visit.

Compare that with the vendor framing. Medable claims its agents can absorb "up to 90% of a CRA's administrative work." The claim ships without an audit, a denominator, or a published method. Both things can be true at once: the tools help, and the marketing runs years ahead of the deployment.

Medical writers and regulatory documentation

Medical writers adopted early. The workflow they describe is scaffolding a first draft, compressing a source document, and running an editing pass, with the output going into human QC rather than out the door.

One first-person account is worth sitting with. A regulatory documentation coordinator posted that an AI vendor had already taken over roughly half of their job's tasks. Not a forecast. A report from inside a function where the work is structured, repetitive, and text-based, which is exactly where these tools land first.

Data management and TMF

Auto-query suggestions, source-to-EDC transfer, and anomaly flagging are real, and adoption is slower than marketed. When practitioners name what they actually touch, they name Rave Companion and Veeva's AI TMF document review. The one adoption number with a named source: a Medidata and Everest Group survey found data integration and standardization is the most common live enterprise use case, at 69.5% of respondents.

Statistical programming gets its own treatment in what AI actually does in statistical programming, so this article won't repeat it.

Can I paste study documents into ChatGPT?

Not into the public one. When a CRA asked about pasting protocol text into ChatGPT, the most-upvoted warning was blunt: "You could get fired/sued dude!" That is roughly correct. The distinction that matters is between consumer LLMs, where your prompts sit outside any data processing agreement your sponsor signed, and a company-contracted private instance covered by contract. Confidentiality clauses in your CTA and the sponsor's data-handling obligations make the public route a genuine firing offense at most organizations.

The practical rules:

• Never put patient data or unredacted source documents into any AI tool, public or private.
• Protocol text is sponsor-confidential even when it contains no patient data.
• Check whether your organization has an approved instance before assuming it doesn't. Regulatory affairs professionals ask each other exactly this: "has anyone's company adopted a confidential pharma GPT?"
• If the tool is free and public, assume everything you type leaves your control.

Does AI actually work for recruitment, protocols, and site selection?

Every claim below carries an evidence grade, because the grades differ more than the headlines suggest.

Patient recruitment and eligibility matching

The numbers in circulation come from vendors. BEKHealth's "3x identification, 93% accuracy," Dyania's "96% accuracy, 170x faster," and Deep6's case studies all appear in the American Hospital Association's 2025 market scan without denominators or independent validation. When practitioners discussed Deep6 directly, the reviews were mixed.

The credible benchmark is NIH's TrialGPT, published in Nature Communications in November 2024. It hit 87.3% criterion-level accuracy, slightly below the human experts it was measured against (88.7 to 90%), and cut screening time by about 40%. It was evaluated on retrospective and synthetic patient cases, not live enrollment. The honest takeaway: faster screening is demonstrated. Improved randomized enrollment is not.

Protocol design and document drafting

This is where 2026 momentum is genuine. The same Medidata and Everest survey found roughly 90% of organizations are using or planning AI for protocol design. When a sponsor-side practitioner asked whether protocol and ICF drafting platforms actually work, the consensus matched what medical writers report: first drafts, yes. Submission-ready documents, no.

Site selection, feasibility, and safety monitoring

IQVIA claims a 90% reduction in feasibility survey completion time. McKinsey credits generative AI site selection with accelerating one program by about 12 months. Both figures come from the party selling the service, with no external audit. Treat them as upper bounds.

Pharmacovigilance is quieter but better evidenced: NLP for adverse-event signal detection has peer-reviewed support, and adherence monitoring runs in production inside DCT platforms. Notably, when practitioners ask which tools have actually made their function easier, the answers stay thin.

What the vendor guides won't tell you

Four omissions recur in every "ultimate guide" on page one of the search results.

Most AI pilots fail

MIT's 2025 "GenAI Divide" report found that 95% of enterprise GenAI pilots produced zero measurable P&L return, against $30 to 40 billion invested. The failures traced to integration and learning gaps, not model quality. Clinical research is a harder-than-average environment for exactly those gaps: regulated, validation-heavy, and built on fragmented data across EDC, CTMS, eTMF, and site systems that barely talk to each other.

The failures nobody names

IBM Watson for Oncology consumed roughly $4 billion. Internal IBM documents obtained by STAT in 2018 showed it recommending "unsafe and incorrect" cancer treatments; MD Anderson walked away after spending about $62 million. The mechanism, thin training data plus expert opinion presented with full confidence, is the same mechanism behind LLM errors today. The technology changed. The failure mode did not.

The AI-native drug companies that review articles still cite as proof have a similar record. BenevolentAI's lead candidate failed Phase 2 and the company delisted. Exscientia discontinued its lead program, merged into Recursion, and Recursion then cut the combined pipeline, along with jobs. As of mid-2026, no AI-designed drug has been approved.

Hallucination has measured rates

In medical text the error rates are quantified. A 2023 study in Cureus by Bhattacharyya and colleagues checked 115 medical references generated by ChatGPT: 47% were completely fabricated, another 46% were real citations containing errors, and only 7% were both authentic and accurate. This is why GxP validation of an LLM workflow is an engineering task with acceptance criteria, not a checkbox on a vendor questionnaire.

The ROI math vendors skip

Integration costs are murkier than the headline savings. One industry compilation, again from DataAlly, a vendor, puts integration at $250,000 to $500,000 per health system with six to eight months of customization before any payoff. No primary study backs those figures, so apply this article's own rule to them. If you are evaluating a tool, tie the business case to cost per randomized patient and screen-failure cost, not to headline percentages. And read self-reported ROI for what it is: QuantHealth's claimed $215 million in client savings comes from its own August 2024 announcement, unaudited.

Will AI replace my clinical research job?

First, separate two things everyone conflates. Clinical research job openings are down about 32% year over year, with more than 26,000 people displaced, per the CCRPS 2025 workforce report; the report publishes no methodology, so treat the exact figures loosely. Most of that is the biopharma funding downturn, not AI task automation. If you lost a role in 2025, a model probably didn't take it. A canceled program did.

The AI exposure varies by role.

ClinOps and SDV. OCR-assisted source data verification is plausible near-term. What has not been demonstrated is the GCP-compliance judgment layered on top of it, which is where practitioners land when they think it through.

Central monitoring and RBQM. ICH E6(R3) pushes sponsors toward risk-based approaches, which makes this a growth area rather than an AI casualty. Someone has to design the risk indicators the algorithms watch.

Data management. The role most often named "first to go", and the one where the most automation already exists. Query volume per study is a number worth watching at your own shop.

Medical writing. The highest explicit anxiety of any function, voiced repeatedly. Drafting time compresses. Accountability for accuracy and the QC signature do not, and someone credentialed still holds them.

Regulatory affairs. The replacement question was asked at least five separate times in that subreddit in 2023 alone. The judgment work, agency interaction, and strategy stay resilient; the document assembly does not.

Where the CRA role is heading is visible in job postings already: toward study integrity manager and quality-lead profiles, less transcription and box-checking, more investigation. On the CRO side, sponsors now ask for AI and RWE capability in RFPs as a differentiator, and the consolidation pressure squeezing mid-size CROs predates AI by a decade.

What do FDA and EMA actually require in 2026?

Practitioners treat the regulatory position as the gate, and asked exactly that when the FDA draft landed. Here is where things stand.

FDA's January 2025 draft guidance proposes a seven-step, risk-based credibility assessment built on two ideas: "context of use" (what exactly the model output is used to decide) and "model risk" (what happens if it is wrong). It remains a draft in mid-2026. The scope boundary most articles get wrong: it covers AI supporting regulatory decision-making about safety, effectiveness, or quality, and explicitly excludes drug discovery and pure operational-efficiency uses. FDA counted more than 500 submissions with AI components since 2016, so the agency is reviewing this material already, guidance or not.

The newest anchor: in April 2026, FDA published a request for information on an "AI-Enabled Optimization of Early-Phase Clinical Trials" pilot program. That is the agency asking industry how AI should reshape early-phase design, which is a different posture from policing it.

EMA moved earlier and finished. Its reflection paper on AI across the medicinal product lifecycle was adopted in September 2024, final rather than draft. It scales expectations by lifecycle stage and patient risk: data integrity, generalisability to the target population, and human oversight throughout, with GMP settings and high-patient-risk uses held to the highest bar. The EU AI Act layers on top of it for European operations.

The practical GxP line for daily work: no LLM output enters a submission without validation scaled to model risk, in the 21 CFR Part 11 and ICH E6 sense of validation. That single sentence is why "just use ChatGPT" fails in regulated documents.

What should I actually learn?

The upskilling threads are the emptiest corner of this topic. People ask for AI courses with a clinical research focus and get almost nothing back. A defensible list for 2026:

• RBQM and central-monitoring concepts. E6(R3) is a regulatory tailwind, and the skills transfer.
• Prompt-assisted document QC, practiced on documents you are contractually allowed to use.
• Data literacy over tool certifications. Tools churn; the ability to read a validation report does not.
• One habit above all: when a vendor quotes a number, ask for the denominator and the independent validation. Most pitches end there.

On the trend forecasts: agentic AI is the 2026 vendor framing, with Gartner's projection that agents will make 15% of day-to-day decisions by 2028 quoted approvingly through Medable. Digital twins, synthetic control arms, and DCT expansion are directional but pre-evidence for most sponsors. Watch them. Don't reorganize a career around them yet.

A closing note on sources. The most reliable signal in this article did not come from any vendor. It came from practitioners comparing notes where no one was selling anything. That is the premise behind Open Label: verified clinical research professionals, writing anonymously, including a salary survey that shows where the compensation actually sits. If you do this work, your notes belong in the comparison.

FAQ

Will AI replace clinical research jobs by 2028?

Not wholesale. Tasks compress, especially drafting, transcription, and query management, but the 2025 displacement numbers trace mostly to the biopharma funding downturn, not automation. The provocative "by 2028" framing describes role reshaping, and even its own text stops short of wholesale replacement.

Is it worth starting a biostatistics career today?

Yes, with an AI-adjacent skill mix. The question comes up because the training path is long, but statistical judgment, estimand thinking, and regulatory literacy remain scarce. See what AI actually does in statistical programming for the task-level picture.

Do sponsors use AI to score vendor RFIs?

It is emerging rather than standard. Practitioner discussion suggests evaluation is still mostly human and relationship-driven, but assume machine-readable structure in your responses matters: clear headings, direct answers, and numbers a parser can find.

How is AI used in clinical trials?

Across the lifecycle: protocol design and eligibility criteria drafting, patient identification and screening, site selection and feasibility, risk-based monitoring, data cleaning and query management, safety signal detection, and submission document drafting. Adoption is deepest in data integration and standardization; every stage keeps human review.

Can I trust what an AI tells me about a trial or drug?

Verify before acting. Measured fabrication rates in medical citations are high, and the working rule practitioners use is the right one: AI flags, humans decide. Treat any uncited claim about a protocol, a drug, or a regulation as unverified until you have checked the source document.